Hong Sukwoo, Mahajan Anita, Laack Nadia N, Link Michael J, Shinya Yuki, O'Brien Erin, Stokken Janalee K, Janus Jeffrey R, Choby Garret W, Van Gompel Jamie J
Department of Neurological Surgery, Mayo Clinic, Rochester, Minnesota, USA.
Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
World Neurosurg. 2023 Oct;178:e510-e519. doi: 10.1016/j.wneu.2023.07.109. Epub 2023 Aug 1.
To compare outcomes of proton radiation therapy (PRT), stereotactic radiosurgery (SRS), and x-ray-based radiation with an SRS boost (XRT + SRS) for newly diagnosed clival chordoma.
Consecutive patients who underwent PRT or SRS in our facility were retrospectively reviewed.
A total of 59 patients were identified (PRT, 36; SRS, 11; XRT + SRS, 12). The mean age (± standard deviation) was 46 ± 20 years, with 54% being male. The mean tumor diameter (± standard deviation) was 3.7 ± 1.5 cm, and 21 (36%) involved the lower clivus. Gross total or near-total resection was attained in 27 patients (46%), all of whom received PRT. PRT was administered with a median prescribed dose of 70.8 Gy (range, 66.0-76.0). SRS involved a median marginal dose of 16 Gy (range, 14-20) and a median maximal dose of 36 Gy (range, 30-45). The XRT + SRS group was treated with an SRS marginal dose of 12.5 Gy (range, 10-20), a maximal dose of 27 Gy (range, 20-40), and an XRT prescription dose of 50.4 Gy (range, 45.0-59.4). Fifteen recurrences were observed (PRT, 6; SRS, 5; XRT + SRS, 4). For the entire cohort (n = 59), recurrence was associated with the degree of resection (P = 0.042), but not with radiation groups (P = 0.98). For patients after subtotal resection or biopsy (n = 32), the SRS ± XRT group was associated with few recurrences (hazard ratio, 0.260; 95% confidence interval, 0.069-0.98; P = 0.046).
Patients after subtotal resection or biopsy may benefit from the incorporation of SRS.
比较质子放射治疗(PRT)、立体定向放射外科治疗(SRS)以及基于X线放射并联合SRS增敏(XRT + SRS)用于新诊断的斜坡脊索瘤的治疗效果。
对在我院接受PRT或SRS治疗的连续性患者进行回顾性分析。
共纳入59例患者(PRT组36例;SRS组11例;XRT + SRS组12例)。平均年龄(±标准差)为46±20岁,男性占54%。平均肿瘤直径(±标准差)为3.7±1.5 cm,21例(36%)累及斜坡下部。27例患者(46%)实现了大体全切或近全切,所有这些患者均接受了PRT治疗。PRT的中位处方剂量为70.8 Gy(范围66.0 - 76.0 Gy)。SRS的中位边缘剂量为16 Gy(范围14 - 20 Gy),中位最大剂量为36 Gy(范围30 - 45 Gy)。XRT + SRS组的SRS边缘剂量为12.5 Gy(范围10 - 20 Gy),最大剂量为27 Gy(范围20 - 40 Gy),XRT处方剂量为50.4 Gy(范围45.0 - 59.4 Gy)。观察到15例复发(PRT组6例;SRS组5例;XRT + SRS组4例)。对于整个队列(n = 59),复发与切除程度相关(P = 0.042),但与放疗组无关(P = 0.98)。对于次全切除或活检后的患者(n = 32),SRS±XRT组复发较少(风险比,0.260;95%置信区间,0.069 - 0.98;P = 0.046)。
次全切除或活检后的患者可能从联合SRS治疗中获益。